Nona Biosciences, a leading global biotechnology company, has announced a strategic collaboration with OverT Bio, a New York-based biotechnology company. This partnership focuses on developing next-generation cell therapies specifically designed to target solid tumors. The collaboration aims to leverage the strengths of both companies, bringing together Nona’s innovative fully human HCAb Harbour Mice® platform with OverT Bio’s expertise in genetic enhancements.
Nona’s proprietary platform generates fully human heavy chain-only antibodies (HCAbs), offering a unique advantage in CAR-based cell therapies. These HCAbs are designed to significantly reduce immunogenicity, making them a more favorable option compared to traditional methods. Their compact size, simplified structure, and precisely calibrated binding properties further enhance their versatility in CAR design. This breakthrough technology has the potential to unlock new therapeutic advancements in the evolving field of cell therapy.
“We are excited to partner with OverT Bio to advance novel cell therapies for solid tumors,” said Dr. Jingsong Wang, Chairman of Nona Biosciences. “By combining our fully human HCAb technology with OverT Bio’s innovative approaches, we aim to accelerate the development of transformative therapies that have the potential to significantly improve patient outcomes.”
Mat Legut, PhD, CEO of OverT Bio, expressed similar enthusiasm, stating, “We are excited to partner with Nona as we are advancing the field of genetically enhanced allogeneic gamma delta T cells. By leveraging Nona’s fully human HCAbs, we are accelerating the development of our first clinical program to demonstrate the safety and efficacy of our differentiated cell engineering platforms.”
This collaboration represents a significant step forward in the fight against solid tumors. By combining Nona’s cutting-edge HCAb technology with OverT Bio’s expertise in genetic enhancements, the partnership holds great promise for the development of new and more effective treatment options for patients.
